(Wiley) A phase 1 clinical trial published in the British Journal of Clinical Pharmacology found that radavirsen–an antisense oligomer that inhibits the production of certain influenza proteins — is safe and well-tolerated in healthy individuals. Additional studies on radavirsen’s potential as a treatment for influenza are warranted.